Brief: Optinose Announces Positive Top-Line Results Of Reopen2, Its Second Phase 3 Clinical Trial Of Xhance For Treatment Of Chronic Sinusitis

OptiNose

13/06/2022 12:18

OptiNose Inc  OPTN.O :
    * OPTINOSE ANNOUNCES POSITIVE TOP-LINE RESULTS OF REOPEN2,
ITS
SECOND PHASE 3 CLINICAL TRIAL OF XHANCE FOR TREATMENT OF CHRONIC
SINUSITIS
    * OPTINOSE INC - SAFETY PROFILE AND TOLERABILITY OF XHANCE
IN THIS
TRIAL WERE GENERALLY CONSISTENT WITH ITS CURRENTLY LABELLED
SAFETY PROFILE
    * OPTINOSE INC - ADVERSE EVENTS OCCURRING AT A RATE OF MORE
THAN
3% WITH XHANCE

Source text for Eikon:  ID:nGNX48xX7Z 
Further company coverage:  OPTN.O